[go: up one dir, main page]

NO20082672L - Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon - Google Patents

Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon

Info

Publication number
NO20082672L
NO20082672L NO20082672A NO20082672A NO20082672L NO 20082672 L NO20082672 L NO 20082672L NO 20082672 A NO20082672 A NO 20082672A NO 20082672 A NO20082672 A NO 20082672A NO 20082672 L NO20082672 L NO 20082672L
Authority
NO
Norway
Prior art keywords
hypertension
treatment
general
systolic
cycletanine
Prior art date
Application number
NO20082672A
Other languages
English (en)
Inventor
Jim Page
Karen Page
Glenn Cornett
Original Assignee
Navitas Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navitas Pharma filed Critical Navitas Pharma
Publication of NO20082672L publication Critical patent/NO20082672L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen tilveiebringer sammensetninger av cikletanin og andre furopyridiner for behandling av økt pulstrykk, isolert systolisk hypertensjon og generell hypertensjon, i monoterapeutiske former (kun furopyridin) og i sammensetninger kombinert med andre antihypertensive midler, kardiovaskulære midler, og/eller oral anti-diabetiske midler. Slike furopyridinsammensetninger inkluderer enantiomerisk rene (positive eller negative) utførelsesformer og ikke-racemiske enantiomerblandinger, og omfatter daglige doser på mindre enn 50 mg. Videre er det tilveiebrakt fremgangsmåter for behandling av generell eller systolisk hypertensjon, pasienter administreres med furopyridinsammensetninger alene eller i kombinasjon med et andre middel for behandling av generell hypertensjon eller systolisk hypertensjon og assosierte komplikasjoner.
NO20082672A 2005-11-09 2008-06-09 Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon NO20082672L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73563205P 2005-11-09 2005-11-09
US75852406P 2006-01-11 2006-01-11
US11/356,158 US20070105817A1 (en) 2005-11-09 2006-02-15 Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
PCT/US2006/043487 WO2007056454A2 (en) 2005-11-09 2006-11-07 Use of cicletanine and other furopyridines for treatment of hypertension

Publications (1)

Publication Number Publication Date
NO20082672L true NO20082672L (no) 2008-07-21

Family

ID=38004571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082672A NO20082672L (no) 2005-11-09 2008-06-09 Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon

Country Status (9)

Country Link
US (1) US20070105817A1 (no)
EP (1) EP1951264A4 (no)
AU (1) AU2006311574A1 (no)
CA (1) CA2632931A1 (no)
EA (1) EA200801305A1 (no)
HR (1) HRP20080255A2 (no)
IL (1) IL192031A0 (no)
NO (1) NO20082672L (no)
WO (1) WO2007056454A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
PL2696865T3 (pl) 2011-04-13 2017-07-31 Thermolife International, Llc Sposoby zastosowania N-acetylo beta-alaniny
WO2015103445A1 (en) * 2013-12-31 2015-07-09 Rockey Don C Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions
US12156886B2 (en) 2020-11-12 2024-12-03 Thermolife International, Llc Methods of increasing blood oxygen saturation
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
IL304991A (en) 2021-02-11 2023-10-01 Thermolife Int Llc A method of administering nitrous oxide gas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN156817B (no) * 1981-02-10 1985-11-09 Scras
GB8330658D0 (en) * 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
GB8808001D0 (en) * 1988-04-06 1988-05-05 Scras Stereospecific preparative process for furol(3,4-c)pyridine derivatives
US5130252A (en) * 1990-05-14 1992-07-14 Synthetech, Inc. Resolution of furopyridine enantiomers and synthetic precursors thereof
TW201305B (no) * 1991-04-03 1993-03-01 Otsuka Pharma Co Ltd
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
AU685898B2 (en) * 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
US5582839A (en) * 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP2003514020A (ja) * 1999-10-29 2003-04-15 ニトロメド インコーポレーテッド 酸化窒素不足により特徴付けられる血管疾患の治療法
US6277860B1 (en) * 1999-10-29 2001-08-21 Pfizer Inc Furopyridine antibacterials
JP4141258B2 (ja) * 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
WO2006128035A2 (en) * 2005-05-26 2006-11-30 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension

Also Published As

Publication number Publication date
IL192031A0 (en) 2011-08-01
HRP20080255A2 (hr) 2008-11-30
EP1951264A4 (en) 2009-03-25
WO2007056454A3 (en) 2007-11-29
CA2632931A1 (en) 2007-05-18
WO2007056454A2 (en) 2007-05-18
US20070105817A1 (en) 2007-05-10
EP1951264A2 (en) 2008-08-06
EA200801305A1 (ru) 2009-06-30
AU2006311574A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
SE0001899D0 (sv) New compounds
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
AU2024259244A1 (en) CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF
WO2007062413A3 (en) Use of parp-1 inhibitors
NO20080244L (no) Doseringsstyring for prasugrel
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
RU2005131578A (ru) Аплидин для лечения множественной миеломы
CA2602290A1 (en) Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
WO2023130028A8 (en) Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
SG146631A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks
WO2024231881A3 (en) Polymorphic forms and formulations of leriglitazone
PE20221314A1 (es) Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro
MD2551G2 (ro) Utilizarea soluţiilor ozonate acceptabile farmaceutic ozonate pentru tratamentul micozelor cavităţii bucale

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application